Navigation Links
Raptor Pharmaceuticals Closes $10 Million Private Placement
Date:6/30/2008

NOVATO, Calif., June 30 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP), today announced that it raised U.S.$10 million through a private placement of 20 million units constituting an aggregate of 20 million shares of the Company's common stock and two-year warrants to purchase 10 million shares of common stock. After deducting placement agent fees, the Company raised $9.3 million in net proceeds from the private placement. The Company intends to use the net proceeds to fund programs for its drug product candidates and execute its corporate strategy.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO)

Each unit was priced at $0.50 and consisted of one share of the Company's common stock and one warrant to purchase one-half share of common stock. Warrants are exercisable for two years from the date of issuance at $0.75 per share during the first year and $0.90 per share during the second year. The units have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from the registration requirements.

Zurich-based Limetree Capital acted as the lead placement agent for the transaction.

Christopher M. Starr, Ph.D., Raptor's co-founder, director and Chief Executive Officer, stated, "We are pleased to have closed this private placement, especially given the challenging financing environment for development-stage biotech companies. We are excited about using the proceeds from this transaction for the advancement of our clinical programs, which we acquired within the past ten months and our internally developed preclinical programs. In the next six to nine months, we expect to have three clinical trials in progress including two trials add
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Raptor Pharmaceuticals Acquires Orphan Clinical Program
2. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
3. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
4. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
5. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... GLEN BURNIE, Md. , Aug. 19, 2014 /PRNewswire/ ... the clinical research industry, recently announced the formation of ... is pleased to announce the addition of Dr. ... Photo - http://photos.prnewswire.com/prnh/20140818/136957 ... insight across a variety of therapeutic areas and set ...
(Date:8/19/2014)... 2014 Sales Horizons, a leader in ... online sales skills training course to help companies ... clinical staff spend the majority of their time on ... center, or physician practice – providing support and education ... there? Sales Horizons believes clinical staff are and should ...
(Date:8/18/2014)... Aug. 18, 2014 BioElectronics Corporation ... consumer medical devices said that its EVP ... by CEOLIVE.TV as part of its Executive ... is available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel ... to investors the unique advantages of BioElectronics ...
(Date:8/18/2014)... NEW YORK , August 18, 2014 /PRNewswire/ ... report published by Transparency Market Research "Life Science ... Culture, Flow Cytometry, Electrophoresis, Chromatography, In-Vitro Diagnostic Reagents ... Research and Academic Institutions, Clinical Laboratories, and Forensic ... and Forecast, 2013 - 2019", the global life ...
Breaking Biology Technology:CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 2Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 5
... BPUR ) today announced its financial results for ... quarter, the company reported a net,loss of $5.8 million, ... loss,of $6.9 million, or $0.53 per common share, for ... on January 31, 2008 and 2007 were,34,971,087 and 15,543,025, ...
... on March 13, 2008 at 9:00 am (Eastern) ... / 6:00 am (Pacific) / 9:00 pm (Beijing/Hong Kong), ... Inc. (NYSE: WX ) ("WuXi PharmaTech" or "the ... company, today announced that it will release unaudited,financial results ...
... Sweden, February 21 With two successful,international ... a new expansion phase. The share issue ... number of significant product,launches in 2008-2009. These ... leading global pharmaceutical companies to meet the,industry,s ...
Cached Biology Technology:Biopure Announces 2008 First Quarter Financial Results 2Biopure Announces 2008 First Quarter Financial Results 3Biopure Announces 2008 First Quarter Financial Results 4Biopure Announces 2008 First Quarter Financial Results 5Biopure Announces 2008 First Quarter Financial Results 6Biopure Announces 2008 First Quarter Financial Results 7WuXi PharmaTech Schedules Fourth Quarter and Full Year 2007 Earnings Release on Wednesday, March 12, 2008 2
(Date:8/20/2014)... DENVER , Aug. 20, 2014  The ... take place in Tampa, Florida ... interactive sessions with Steven Rahman, Director, Technology and Strategy ... Sector at Experian. The theme of this year,s ... and Privacy. "Biometrics UnPlugged: Mobility ...
(Date:8/19/2014)... Can nutrition rating systems be used in supermarkets to ... University researchers sought to answer that very question by ... uses the Guiding Stars System to rate the nutritional ... Cornell Food and Brand Lab,s David Just, PhD, and ... studied the sales records of over 150 Hannaford Supermarkets ...
(Date:8/19/2014)... not a lemur. It,s not an African Bush Baby or ... adorable and downright "cool" primate from Southeast Asia. , "It,s ... said Rafe Brown, curator-in-charge at the University of Kansas, Biodiversity ... cute, furry body; a long tail with a furry tuft ... that look a bit like the disks on the digits ...
Breaking Biology News(10 mins):Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3
... American eels are fast disappearing from restaurant menus as ... the reasons for the eel decline remain as mysterious ... NOAA scientist and colleagues in Japan and the United ... primary factor in declining reproduction and survival rates. ...
... Matyjaszewski have created a version of Harry Potters famed invisibility cloak for ... Through a collaborative effort, ... developed a new design paradigm that makes particles invisible. , ... In a recent edition of Advanced ...
... cancer immune therapy have made an unexpected find: They,ve ... inflammatory bowel disease (IBD), a cluster of conditions that ... and diarrhea. , The two most common forms ... in extreme cases, they can be fatal. The mouse ...
Cached Biology News:Changes in ocean conditions in Sargasso Sea potential cause for decline in eel fishery 2Changes in ocean conditions in Sargasso Sea potential cause for decline in eel fishery 3Carnegie Mellon researchers create invisibiity cloak 2Scientists successfully treat new mouse model of inflammatory bowel disease 2
... Varioskan is a high performance spectral ... and incubator. With the advanced SkanIt ... reliability for drug discovery assay development. ... fluorescence intensity, time-resolved fluorescence and photometric ...
Immulon 2 HB 1x8 Strip assembled, C-bottom; high binding irradiated surface to provide increased binding affinity for hydrophilic proteins and complexes....
... The Jouan RCT series of refrigerated cold ... to trapping of low volatility/aqueous solvents or ... RC10 and other vacuum concentrators/centrifugal evaporators. Also ... cooling systems such as used in electron ...
Immulon 2HB, Flat Bottom, 50/Bx; high binding irradiated surface to provide increased binding affinity for hydrophilic proteins and complexes....
Biology Products: